6 completed, 2 unknown, 1 recruiting. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Unknown 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow AndroGel: new trials by email Literature Review of AndroGel trials Research Report on AndroGel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy Testosterone gel, Placebo - Prostatic Neoplasms, Hypogonadism | Phase 3 | Recruiting | Canisius-Wilhelmina Hospital | 140 | 2022-12-12 | 2025-05-02 |
| Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study Testosterone gel, Placebo - Disorder of Sex Development, 46,XY | Phase 3 | Unknown | Erasmus Medical Center | 1 | 2021-06-01 | 2021-04-05 |
| Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort Testosterone, Estradiol - Fertility Disorders | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 26 | 2017-08-01 | 2017-08-03 |
| Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men SOV2012-F1, AndroGel - Hypogonadism, Male | Phase 3 | Completed | Marius Pharmaceuticals | 314 | 2017-07-05 | 2023-06-28 |
| Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel) - Male Hypogonadism | Phase 3 | Completed | Clarus Therapeutics, Inc. | 182 | 2012-08-01 | 2021-06-28 |
| PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate placebo acyline, placebo gel, Testosterone 1% gel 1.25 g - Healthy | Phase 2 / Phase 3 | Completed | University of Washington | 62 | 2011-10-01 | 2017-10-05 |
| Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients Testosterone, Placebo - Advanced Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 53 | 2009-09-01 | 2016-09-13 |
| Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Androxal, AndroGel, Placebo - Secondary Hypogonadism | Phase 3 | Completed | Repros Therapeutics Inc. | 194 | 2006-03-01 | 2010-02-11 |
| Exercise and Testosterone Therapy in Elderly Men With Physical Frailty Transdermal Testosterone gel (1%), Supervised exercise training - Physical Frailty, Hip Fracture | Phase 3 | Completed | Washington University School of Medicine | 25 | 2004-11-01 | 2018-02-22 |
Hypogonadism (3) · Eunuchism (2) · Disorder of Sex Development, 46,XY (1) · Fatigue (1) · Hip Fractures (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Canisius-Wilhelmina Hospital (1) · Clarus Therapeutics, Inc. (1) · Erasmus Medical Center (1) · Hospital de Clinicas de Porto Alegre (1) · M.D. Anderson Cancer Center (1) · Marius Pharmaceuticals (1) · Repros Therapeutics Inc. (1) · University of Washington (1) · Washington University School of Medicine (1)
United States (6) · Netherlands (2) · Germany (1)
Alastair Smith, MB, ChB (1) · Andre van As, MD, PhD (1) · Diederik Somford, MD, PhD (1) · Ellen F. Binder, MD (1) · Laura de Graaff, MD, PhD (1) · Om Dhingra, PhD (1) · Ronald Swerdloff, MD (1) · Rony Dev, DO (1) · Stephanie T Page, MD, PhD (1)
PMID 27172434, PMID 36272969, PMID 38606384, PMID 40514343
R01AG037603 (1)